ROARABLE
Today ⌘ Pro Terminal Big Ideas 🎲 Predictions Screener 🦋 Butterfly 8 Analysts 🏛️ Policy 🎬 Video ★ Watchlist 🎲 Prediction Markets 📊 RQD Track Record 📅 Next Catalysts 🛡️ Overlap & Crash X-Ray 📰 Live Wire 🐋 13F Whales 🏛️ Congress & CEO Buys 🏆 $100K Arena ⌘ Pro Terminal 📐 Methodology & Corrections
Stock Ratings / Health Care / NMTC / forecast
AEMD (36) PLSM (47) FEMY (30) ICU (31) ⌘ Pro Terminal →

NeuroOne Medical Technologies Corporation (NMTC) 12-Month Stock Forecast & Price Target Cone

$0.93 -4.39% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $0.92

NeuroOne Medical Technologies Corporation (NMTC) carries a Roarable Rating of E (Strong Sell) with 33/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

📊 Historical Track Record Warning: Scores below 50 (33/100 · E) historically underperformed SPY in 71% of rolling 90-day windows →
ROARABLE E • RED ALERT Cap $8.4M
📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on NMTC Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is NMTC stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼

As of 2026-11-03, NeuroOne Medical Technologies Corporation (NASDAQ: NMTC) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 33/100 at a spot price of $0.93 (-4.39% 1D, market cap $8.4M). Pillar breakdown: Fundamental Cash Engine 8/20, Institutional 13F & Options Flow 3/20, Executive Insider Alignment 11/20, FRED Macro Regime Fit 6/20, and SEC Balance-Sheet Forensics 5/20. Across 1016 tracked Health Care issuers, NMTC ranks #701 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does NMTC compare to AEMD and PLSM in the Health Care sector?
▼

Within the Health Care sector (Medical/Dental Instruments), NMTC carries a Roarable E (33/100 RQD), trailing P/E of N/A, gross margin of 56.5%, and ROIC of -35.0%. By comparison, AEMD (Aethlon Medical Inc.) holds a D- grade (36/100 RQD, P/E N/A, ROIC -35.0%, cap $8.7M) and PLSM (Pulsenmore Ltd.) posts a D grade (47/100 RQD, P/E N/A, ROIC —, cap $10.9M). Among the 5-stock peer group, NMTC leads on earnings multiple (N/A) while NMTC leads on capital efficiency (-35.0% ROIC).

✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for NMTC?
▼

Per NMTC's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-09-30, CIK 0001500198), NeuroOne Medical Technologies Corporation generated $9.1M in revenue (+163.5% YoY), -$3.6M in net income, and -$2.9M in free cash flow against $8.6M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
🛡️ Portfolio Crash X-Ray
EXT / AFTER-HRS: $0.92 (-0.98%)🧬 Disciplined Float (+0.72% YoY Shares)⚙️ Cash Engine: 8/20 (D-) • 0% FCF Margin
Verify 90D Bucket Audit →
📊 Historical Track Record Warning: Scores below 50 (33/100 · E) historically underperformed SPY in 71% of rolling 90-day windows (-8.9% avg 90D alpha vs SPY • 29.0% hit rate).
Audit Bucket Track Record →
RQD QUANT TACHOMETERRED ALERT • E
025507510033
2-of-3 JEV AI Jury Bearish Warning
Cash
SEC
Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw E · Rk D-
Cash (8)Whales (3)SEC (11)Macro (6)CEO (5)
Each axis scored 0–20
12M PRICE TARGET CONE-10.8% Base Target
$6 Bull$1 Base$1 Bear
📬 FREE NMTC RATING-CHANGE & BRIEFING ALERTSManage / Unsubscribe
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for NMTC)Realized 20D OHLCV Swing Band: ±12.5%
Deterministic 5-Pillar Attribution (33/100 Composite)
🔍 WHY NMTC SCORES 33/100 (E) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: SEC 10-K Forensic Risk+11/20 pts (33% of score)

Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 5/9

▲ #2 Bullish Driver: Cash Engine Quality+8/20 pts (24% of score)

SEC XBRL FY 2025 (10-K): 0% FCF Margin ($0 FCF) & 56.5% Gross Margin

▼ #1 Drag / Risk Factor: Whale & Options Positioning4/20 pts (-16 pt drag)

Put hedging (50% put share) caps near-term gamma upside (-16 pts vs max)

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)
41
Grade D$1.10-10.9% Next Q
Q2 (-2Q)
38
Grade E$0.98-13.3% Next Q
Q3 (-1Q)
36
Grade E$0.85+9.4% Next Q
Current
33
Grade E$0.93-8.9% Hist 90D α
Trajectory: D (41) → E (33)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a NMTC Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While NMTC currently carries a cautious 33/100 (E) rating due to Whale & Options Positioning (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($1.28) and Max Pain ($0.98) forces dealer call-delta covering toward $6.43.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Disciplined Float (+0.72% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $NMTC• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “NMTC Beats Next Quarter EPS Consensus (Dec 29, 2026) & Holds Above 200D SMA”
YES 33%NO 67%Trade / Inspect Odds →
INTERACTIVE 12-MONTH POSITION SIMULATOR

Drag to Test Your NMTC Position Size: $10,000

Shares at $0.93: 10752.7 sh
$1,000$10,000$25,000$50,000$100,000
12M Bear Case FloorTarget $0.65
$6,989
$-3,011 (-30.1%)
12M Consensus BaseTarget $0.83
$8,925
$-1,075 (-10.8%)
12M Bull Case BreakoutTarget $6.43
$69,140
+$59,140 (+591.4%)

Wall Street Analyst Breakdown & Historical Accuracy Audit (35 Desks)

Street Historical Accuracy: 64/100
● Strong Buy / Buy: 17● Hold: 9● Sell: 9
Wall Street FirmStance12M Target1Y AccuracyTrack Grade
Morgan StanleyInstitutional Equity DeskHOLD$174%A
Goldman SachsSector Coverage LeadUNDERPERFORM$669%B
JP MorganUS Large-Cap ResearchSELL$158%C
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring NMTC)

  • ✓Walkthrough of NMTC's RQD Radar, SEC cash-conversion gap & downside invalidation levels
  • ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
  • ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
Join Founding VIP Waitlist (No Card Required) →$100K Arena
NMTC // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -79.29%🛡️ HOLDING TREND SUPPORT
2026-11-03O $0.97H $0.97L $0.93C $0.93VOL 33.8K
RES: $2.64SUP: $0.70SMA50: $1.28SMA200: $3.16
$5.16$3.97$2.78$1.59$0.40RES $2.64SUP $0.70$0.932026-05-042026-06-172026-08-042026-09-182026-11-03
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

NMTC Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 NMTC Butterfly Map → + Track NMTC →
Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)
8.0%/yr Implied 5Y Growth

vs. +163.5% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on NMTC today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for NMTC. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for NMTC today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (NMTC)

Health Care Rank #701 of 1016 ⚔️ AEMD vs NMTC Full Matrix →

1. Head-to-Head Health Care Peer Comparison (NMTC vs. AEMD, PLSM, FEMY, ICU)

Industry: Medical/Dental Instruments (120 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, NeuroOne Medical Technologies Corporation (NMTC) ranks #701 by composite RQD confidence (33/100, grade E) and #907 by equity capitalization ($8.4M). Within this direct 5-issuer industry benchmark cohort, NMTC leads on earnings valuation at N/A trailing P/E, while NMTC leads on capital efficiency and profitability with -35.0% ROIC and 56.5% gross margin. PLSM currently holds the highest overall quantitative score in the immediate peer group at 47/100 (D) compared with NMTC at 33/100 (E).

Ticker / Company Roarable Grade RQD Score Trailing P/E Gross Margin ROIC 1D Change Market Cap Head-to-Head
NMTC ACTIVE
NeuroOne Medical Technologies Corporation
E 33/100 — 56.5% -35.0% -4.39% $8.4M Benchmark Subject
AEMD
Aethlon Medical Inc.
D- 36/100 — — -35.0% -1.45% $8.7M /aemd-vs-nmtc →
PLSM
Pulsenmore Ltd.
D 47/100 — — — +3.09% $10.9M /plsm-vs-nmtc →
FEMY
Femasys Inc.
E 30/100 — 62.0% -35.0% +1.11% $11.5M /femy-vs-nmtc →
ICU
SeaStar Medical Holding Corporation
E 31/100 — 95.7% -35.0% -3.03% $11.8M /icu-vs-nmtc →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-09-30 • CIK 0001500198

In its most recent audited fiscal period (FY2025, filed 2025-09-30), NeuroOne Medical Technologies Corporation (NMTC) reported GAAP revenue of $9.1M (+163.5% vs. FY2024 revenue of $3.5M , and +366.0% cumulative change since FY2023) , GAAP net income of -$3.6M, operating cash flow of -$2.8M, and free cash flow of -$2.9M (+73.8% YoY). On the balance sheet, NMTC closed FY2025 with $8.6M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 5/9).

Fiscal Period Filing Date Revenue Net Income Operating Cash Flow Free Cash Flow Total Assets Total Debt
FY2025 (FY) 2025-09-30 $9.1M -$3.6M -$2.8M -$2.9M $8.6M —
FY2024 (FY) 2024-09-30 $3.5M -$12.3M -$11.0M -$11.1M $6.5M —
FY2023 (FY) 2023-09-30 $2.0M -$11.9M -$12.9M -$12.9M — —

3. NMTC Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is NMTC stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-03, NeuroOne Medical Technologies Corporation (NASDAQ: NMTC) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 33/100 at a spot price of $0.93 (-4.39% 1D, market cap $8.4M). Pillar breakdown: Fundamental Cash Engine 8/20, Institutional 13F & Options Flow 3/20, Executive Insider Alignment 11/20, FRED Macro Regime Fit 6/20, and SEC Balance-Sheet Forensics 5/20. Across 1016 tracked Health Care issuers, NMTC ranks #701 in composite RQD confidence.

How does NMTC compare to AEMD and PLSM in the Health Care sector?

Within the Health Care sector (Medical/Dental Instruments), NMTC carries a Roarable E (33/100 RQD), trailing P/E of N/A, gross margin of 56.5%, and ROIC of -35.0%. By comparison, AEMD (Aethlon Medical Inc.) holds a D- grade (36/100 RQD, P/E N/A, ROIC -35.0%, cap $8.7M) and PLSM (Pulsenmore Ltd.) posts a D grade (47/100 RQD, P/E N/A, ROIC —, cap $10.9M). Among the 5-stock peer group, NMTC leads on earnings multiple (N/A) while NMTC leads on capital efficiency (-35.0% ROIC).

What are the biggest fundamental strengths and SEC risk factors for NMTC?

Per NMTC's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-09-30, CIK 0001500198), NeuroOne Medical Technologies Corporation generated $9.1M in revenue (+163.5% YoY), -$3.6M in net income, and -$2.9M in free cash flow against $8.6M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is NMTC trading relative to its 50-day, 200-day, and 52-week technical levels?

NMTC last traded at $0.93 (-4.39% on volume of 33,829 shares), positioning the stock -27.34% below its 50-day simple moving average ($1.28) and -70.57% below its 200-day simple moving average ($3.16). Across its 52-week range of $0.77 to $6.12, NMTC sits at the 3.0% percentile with a 14-day RSI of 40.9 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($1.00 to $1.05).

Direct Sub-Reports: NMTC RQD Cockpit NMTC 12M Forecast NMTC Earnings & Move NMTC Dividends & DRIP NMTC Insiders & 13F NMTC Whale Options NMTC Profit Sankey NMTC News & Why
ROARABLE RATING BRIEF • RQD 33/100 (E) ✓ STAGE-C NUMBER FIREWALL VERIFIED

NMTC — NeuroOne Medical Technologies Corporation: What the Facts Mean to a Prospective Investor

Engine: anthropic/claude-haiku-5.5
As of: 2026-11-02T15:52:09Z

Roarable Rating Brief: What This Means to a Prospective Investor

Per the Roarable RQD rating, NMTC scores 33 out of 100 with a letter grade of E, labeled "Roarable Strong Sell — Forensic Risk / Avoid." The five pillars are:

  • Fundamental Cash Engine: 8 / 20. The rating cites ROIC of -35% and an FCF yield of 0%.
  • Whale 13F Flow: 3 / 20. Institutional accumulation and options positioning scored near the bottom of the range. Investors should read this as weak evidence of large-holder conviction.
  • Insider Conviction: 5 / 20. SEC Form 4 and Congressional PTR cluster flow scored low, indicating limited insider-side confirmation of the thesis.
  • Macro Regime Fit: 6 / 20. Beta is 1.0 with sector sensitivity noted. The rating does not indicate a macro tailwind that would offset the company-specific weaknesses.
  • Forensic Balance Sheet: 11 / 20. The rating cites Altman Z 2.5, Piotroski F 5/9, and Debt/Equity 0.5. This is the strongest pillar but still mid-range, meaning balance sheet risk is present but not the dominant concern.

Taken together, the valuation tradeoff is that a stock trading at $0.97 with an $8.8M market capitalization is priced as a speculative, high-variance situation. The upside drivers would need to come from a turnaround in operating economics, which the current rating does not support. The principal risk is that weak cash generation and low institutional and insider conviction leave little cushion if the company must raise capital or if revenue growth does not convert to earnings.

Business

NeuroOne Medical Technologies Corporation is a NASDAQ-listed issuer in the Health Care sector, within the Medical/Dental Instruments industry.

Recent Catalysts & News Wire Analysis

Per the recent news wire, the most significant catalyst is a Quiver Quantitative report (GREEN, CATALYST) describing preliminary fiscal Q4 and full-year 2026 product revenue growth that topped guidance with a record $4.5 Million order. Other items (YELLOW, MARKET WIRE) are aggregator and forum coverage of NMTC market action and a Stock Titan item on a brain drug-delivery platform's first drugmaker order. These headlines are generic in summary text; the substantive fact in the record is the order and revenue commentary. Watch items include whether the order and growth translate into sustained cash flow, given the reported operating losses. The Butterfly supply-chain graph reports no proprietary signals.

Butterfly Effect: 2nd-Order Supply-Chain & Sector Ripples

Per the Butterfly Supply-Chain Graph, supply chain status is NONE, with no butterfly links and no proprietary signals. A prospective investor should monitor whether the drugmaker order relationship expands into recurring demand, since that would be the primary second-order dependency suggested by the news wire, but the graph does not map it.

Open Questions

  • What are the specific products and customers behind the reported $9.1M FY 2025 revenue, and how much is attributable to the drugmaker order?
  • Why is EPS, debt, and forward valuation missing, and what is the current share count underlying the $8.8M market capitalization?
  • What is the cash runway given $3.6M of cash against FY 2025 negative free cash flow of $-2.9M?
  • Does the preliminary FY 2026 revenue growth come with a credible path to positive operating income?
  • What drove the stock's 52-week range from $0.77 to $6.12 and the 12.96% move in the latest session?

NMTC Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for NeuroOne Medical Technologies Corporation (NMTC) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to NMTC Debate Forum (3) ↓
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

NMTC Bull vs. Bear Conversation Board — What's Your Call at $0.93?

🐂 33% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON NMTC 🐻 67% BEARISH CONVICTION
1. Pick Your Side on NMTC:
💡 Tip: Back up your call with a price target or RQD metric to get upvoted to the top.
RO RoarDesk_Moderator Roarable Research Desk 🐻 BEARISH 🎯 Target: $0.85 (-12.4%)
📌 Pinned Debate

🔥 Official Bull vs. Bear Debate: Is NMTC (E • RQD 33/100) a Buy at $0.97?

Welcome to the NMTC (NeuroOne Medical Technologies Corporation) Roar Pit. Current RQD Composite is 33/100 (Roarable Strong Sell — Forensic Risk / Avoid) in Medical/Dental Instruments. Bulls point to operating leverage and sector positioning, while bears focus on macro rate sensitivity and margin execution. Pick your side (🐂 Bull or 🐻 Bear) and drop your price target below.

SK SkepticalCFA Forensic Accounting Watch 🐻 BEARISH 🎯 Target: $0.81 (-16.5%)
Spot @ $0.97

Pump the brakes on NMTC — check the valuation vs. margin headwinds

Everyone in here is repeating the bull case on NMTC, but look at what you are paying: current EV/EBITDA multiples with 56.5% gross margins. Unless NeuroOne Medical Technologies Corporation expands free cash flow yield next quarter, I would rather wait for a pullback closer to the 200-day moving average before touching this.

MI MidwestValue Verified K Arena Trader 🐂 BULLISH 🎯 Target: $1.15 (+18.6%)
Spot @ $0.97

NMTC cash flow & RQD setup is being underpriced by the Street here

Looking at the 5-pillar RQD breakdown on NMTC, the market is fixating on short-term headline noise in Medical/Dental Instruments and ignoring the balance sheet and cash flow trajectory. At $0.97 (52-wk range $0.77 - $6.12), any beat on forward guidance forces shorts and underweight funds to chase.

LIVE TAPE SPY $752.10 -1.80% QQQ $681.09 -3.60% DIA $519.34 -1.08% IWM $279.14 -1.68% NVDA $204.64 -4.22% AAPL $344.63 -1.23% MSFT $521.91 -1.55% TSLA $399.81 -0.86% PLTR $184.11 -6.27% SOFI $16.76 -4.83% IBIT $43.35 -5.42% GLD $361.65 -3.59%